Company Filing History:
Years Active: 2011-2014
Title: **Innovator Spotlight: Normand R. Richard**
Introduction
Normand R. Richard is an accomplished inventor based in Ramona, California, recognized for his significant contributions to the field of biotechnology. With a total of two patents to his name, Richard has made strides in understanding immunomodulatory drug activity, furthering the potential for advancements in medical diagnostics and patient care.
Latest Patents
Richard's latest patents focus on the use of micro-RNA as a biomarker for assessing the activity of immunomodulatory compounds. These patents detail methods for measuring the presence of microRNA in patient samples, providing valuable insights into the effectiveness of immunomodulatory treatments. Additionally, the innovations include techniques for assessing patient compliance in individuals undergoing treatment with these compounds, which is crucial for improving health outcomes.
Career Highlights
Normand R. Richard is associated with Celgene Corporation, an organization at the forefront of biopharmaceutical innovations. His work has contributed to the development of novel therapeutic strategies aimed at enhancing the effectiveness of existing immunomodulatory therapies. Richard's expertise in molecular biology and his dedication to research have solidified his reputation as a leading inventor in the industry.
Collaborations
Throughout his career, Richard has collaborated with esteemed colleagues such as Gregory D. Ferguson and Helen A. Brady. These partnerships have fostered a creative environment for innovation, allowing for the exchange of ideas and collaboration on groundbreaking research projects that aim to transform patient care in the field of immunology.
Conclusion
Normand R. Richard's contributions to the science of immunomodulatory drugs illustrate the vital role of innovative thinking in advancing healthcare. His patents not only impact the field of biotechnology but also provide a pathway for future research and development in patient compliance and treatment efficacy. As he continues his work at Celgene Corporation, Richard remains a key figure in the evolution of therapeutic strategies that could significantly benefit patients worldwide.